V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330009284 | 330006094 | 1.68 | 71.65 | Palliative (P) | 2014-05-12 | 2014-05-12 | Cetuximab+Cisplatin+FU (> Cycle 2) | 02 | N | 330015473 | CISPLATIN + VINORELBINE |
| 330009285 | 330009319 | null | null | Neo-adjuvant (N) | 2013-08-09 | 2013-08-09 | STS Rhabdomyosarcoma RMS 2005 VA | 2 | N | 330015685 | CLADRIBINE |
| 330009286 | 330009319 | 1.79 | null | Palliative (P) | 2015-12-08 | 2015-12-11 | Alemtuz+Fludara+Melphalan RIC MUD | null | N | 330015685 | BUSULFAN + MELPHALAN |
| 330009287 | 330009320 | 1.67 | 60.8 | Palliative (P) | 2018-03-27 | 2018-03-27 | Doxorubicin + Ifosfamide | N | N | 330015691 | CISPLATIN + GEMCITABINE |
| 330009288 | 330009320 | 1.61 | null | Palliative (P) | 2015-05-21 | 2015-09-18 | PEMBROLIZUMAB | Y | N | 330015691 | VDC |
| 330009289 | 330006097 | 1.78 | 72.2 | Palliative (P) | 2018-04-02 | 2018-04-03 | Hydroxycarbamide | N | N | 330015923 | IBRUTINIB |
| 330009290 | 330006098 | 1.79 | 73.7 | Palliative (P) | 2014-08-15 | 2014-08-18 | Vinorelbine (oral) | 02 | N | 330016127 | HYDROXYCARBAMIDE |
| 330009291 | 330006099 | 1.8 | 74.2 | Curative (C) | 2014-07-04 | 2014-07-08 | CETUXIMAB + CISPLATIN + FU | N | null | 330016127 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330009292 | 330006099 | null | 73 | Palliative (P) | 2014-03-12 | 2014-08-03 | Gemcitabine + Oxaliplatin | N | N | 330016127 | CVP |
| 330009293 | 330006099 | 1.8 | 54.7 | Palliative (P) | null | 2016-07-26 | MELPHALAN | N | N | 330016127 | CVP R |
| 330009294 | 330006100 | 1.7 | 61 | Adjuvant (A) | 2014-06-08 | 2014-06-09 | Doxorubicin + Methotrexate | 2 | N | 330016561 | POMB/ACE |
| 330009295 | 330006103 | 1.79 | 74 | Palliative (P) | 2016-01-18 | 2016-01-20 | GEMCITABINE | 2 | N | 330016774 | PAZOPANIB |
| 330009296 | 330006104 | null | null | Disease modification (D) | 2014-10-10 | 2014-11-07 | Cisplatin + Gemcitabine (D 1 & 8) | Y | N | 330016794 | CYCLOPHOSPHAMIDE + VINCRISTINE + LIPOSOMAL DOXORUBICIN |
| 330009297 | 330006104 | 1.63 | 60.8 | Palliative (P) | 2017-12-18 | 2017-12-18 | CASPS TRIAL | 2 | N | 330016794 | CYCLOPHOSPHAMIDE |
| 330009298 | 330011081 | 1.83 | null | Neo-adjuvant (N) | 2016-02-03 | 2017-04-13 | BENDAMUSTINE | 02 | N | 330017182 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330009299 | 330011081 | 1.79 | 72.8 | Disease modification (D) | 2016-06-20 | 2016-06-21 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 2 | N | 330017182 | CVP R |
| 330009300 | 330011081 | 1.77 | 83.8 | Disease modification (D) | 2016-01-14 | 2016-03-31 | MVAC Accelerated | N | null | 330017182 | BENDAMUSTINE |
| 330009301 | 330006105 | 1.71 | 64.5 | Curative (C) | 2014-11-07 | 2014-11-07 | Bortezomib + Cyclophos + Dex | Y | N | 330018865 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330009302 | 330006106 | 1.64 | 70 | Palliative (P) | 2018-04-08 | 2018-04-10 | CNS LGG 2004 03 vinc weekly+ carbo | 02 | N | 330018870 | PAC-E |
| 330009303 | 330009327 | 0 | 79.65 | Curative (C) | 2016-12-14 | 2016-12-18 | CISPLATIN + VINORELBINE | 02 | N | 330018870 | TOPOTECAN |
| 330009304 | 330009327 | null | null | Neo-adjuvant (N) | 2016-11-09 | 2016-11-12 | PEMBROLIZUMAB | N | null | 330018870 | TRIPLE INTRATHECAL |
| 330009305 | 330009327 | 1.82 | 48 | Palliative (P) | 2016-12-10 | 2017-10-09 | CAPECITABINE + CETUXIMAB + CISPLATIN | N | N | 330018870 | FLUOROURACIL + MITOMYCIN + RT |
| 330009306 | 330006107 | 1.7 | 0 | null | 2019-03-22 | 2019-03-22 | Capecitabine | 02 | N | 330019201 | MA |
| 330009307 | 330006108 | 1.6 | 11.1 | Disease modification (D) | 2016-01-31 | 2016-07-18 | BENDAMUSTINE | N | N | 330019649 | EMA/CO |
| 330009308 | 330006108 | null | null | null | null | 2015-06-28 | Gemcitabine weekly | N | N | 330019649 | CYTARABINE |
| 330009309 | 330006109 | null | 106 | Curative (C) | 2019-06-04 | 2019-06-04 | Dox + HD Mtx (post PAM) | 1 | N | 330020049 | MELPHALAN |
| 330009310 | 330006109 | 1.82 | 62.2 | Palliative (P) | 2016-02-13 | 2016-02-22 | Carboplatin + Cetux + FU (>Cycle 2) | 02 | N | 330020049 | IDARUBICIN |
| 330009311 | 330006110 | 1.04 | null | null | 2018-08-18 | 2018-08-23 | CYTARABINE + DAUNORUBICIN + ETOPOSIDE | N | null | 330020297 | UKALL60+ |
| 330009312 | 330006112 | 1.7 | 16.1 | null | 2017-08-29 | 2017-09-11 | Hydroxycarbamide | N | null | 330020339 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330009313 | 330006115 | 1.55 | 65 | Palliative (P) | 2018-11-16 | 2018-11-21 | AML17 TRIAL | 2 | N | 330020434 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 330009314 | 330006116 | 1.63 | 80.2 | Curative (C) | 2013-06-10 | 2013-06-12 | UKALL14- Ph 1 Induction | 02 | N | 330020434 | DOXORUBICIN + IFOSFAMIDE |
| 330009315 | 330006117 | 1.76 | 56 | Disease modification (D) | 2017-02-06 | 2017-02-06 | Dox + HD Mtx (post PAM) | null | null | 330020661 | CHOP R + BORTEZOMIB |
| 330009316 | 330006118 | 1.6 | 0 | Palliative (P) | 2016-11-23 | 2016-11-23 | LENALIDOMIDE | N | N | 330020704 | FLUOROURACIL + MITOMYCIN + RT |
| 330009317 | 330006118 | 1.6 | 61.6 | Curative (C) | 2017-01-07 | 2017-10-20 | Trastuzumab Subcutaneous | N | N | 330020704 | KESTREL TRIAL |
| 330009318 | 330006119 | 0 | 68.2 | Palliative (P) | 2017-10-09 | 2017-10-09 | CTD | N | N | 330020744 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330009319 | 330006120 | 1.8 | 98.5 | Curative (C) | 2017-05-26 | 2017-05-30 | BEP 5 Day | 02 | N | 330020797 | CARBOPLATIN + PEMETREXED |
| 330009320 | 330011089 | 1.59 | 55.5 | null | 2018-08-06 | 2018-08-06 | Cyclophosphamide + Vincristine | N | null | 330020918 | UKALL2014 |
| 330009321 | 330009340 | 1.69 | null | Curative (C) | null | 2019-05-14 | UKALL XII Maintenance (3 months) | null | N | 330020943 | GEMCITABINE |
| 330009322 | 330012043 | null | 10.4 | Disease modification (D) | 2016-05-23 | 2016-05-27 | GC Int Guide Excranial GermCell JEB | N | null | 330020986 | DOXORUBICIN + HD MTX |
| 330009323 | 330006126 | 1.76 | null | Neo-adjuvant (N) | 2017-05-23 | 2017-09-15 | BORTEZOMIB + RITUXIMAB | 2 | N | 330021072 | BEVACIZUMAB + IRINOTECAN |
| 330009324 | 330009341 | 0.76 | 64.1 | Neo-adjuvant (N) | 2015-07-28 | 2015-09-03 | CAELYX + CYCLOPHOSPHAMIDE + VINCRISTINE | Y | N | 330021072 | CYTARABINE + MITOXANTRONE |
| 330009325 | 330006130 | 1.75 | 69 | Palliative (P) | 2014-12-25 | 2014-12-26 | MACE | N | N | 330021094 | CISPLATIN + DOXORUBICIN + METHOTREXATE |
| 330009326 | 330006130 | 1.7 | 54.3 | Neo-adjuvant (N) | 2018-02-19 | 2018-03-12 | MA (Cytarabine 3g/m2) | Y | N | 330021094 | DOXORUBICIN + HD MTX |
| 330009327 | 330011093 | 1.98 | 19.1 | Curative (C) | 2016-08-08 | 2016-08-08 | Venetoclax | N | N | 330021332 | BENDAMUSTINE |
| 330009328 | 330013101 | 0 | 89 | Curative (C) | 2014-01-27 | 2014-01-27 | AML17 TRIAL | 02 | N | 330021404 | CARBOPLATIN + VINCRISTINE |
| 330009329 | 330006132 | 1.83 | 78 | Adjuvant (A) | 2015-10-26 | 2015-11-21 | Cetuximab+Cisplatin+FU (> Cycle 2) | 2 | null | 330021494 | UKALL2014 |
| 330009330 | 330006134 | 1.67 | 106 | Palliative (P) | 2016-09-18 | 2016-09-18 | EDP | 02 | null | 330021497 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE |
| 330009331 | 330006134 | 1.83 | 70 | Palliative (P) | 2017-01-29 | 2017-03-04 | IBRUTINIB | Y | N | 330021497 | DACTINOMYCIN + CYCLO + VINCRISTINE |
| 330009332 | 330006135 | 1.62 | null | null | 2016-10-16 | 2016-11-04 | UKALL14- Intens/CNS Proph | N | N | 330021705 | NELARABINE |
| 330009333 | 330012046 | 1.68 | 65.45 | Palliative (P) | 2018-10-20 | 2018-10-20 | Eribulin | 2 | N | 330021777 | CVD (NEUROENDOCRINE) |